ADC Therapeutics (ADCT) Conference Transcript

Summary of ADC Therapeutics Conference Call Company Overview - ADC Therapeutics (ADCT) is an integrated company with development and commercial stage capabilities, currently marketing ZENLANTA, approved for third-line plus DLBCL [3][4] Product Details - ZENLANTA: - Approved for third-line plus DLBCL - Efficacy characterized by rapid (median duration to CR in 1.5 months), deep (high response rate), and durable (median duration of response not achieved after two years) efficacy [5][6][7] - Manageable side effect profile without irreversible toxicities associated with chemotherapy [6][7] - Administered as a 30-minute infusion every three weeks for up to eight cycles [7] Financial Performance - Sales maintained at approximately $16 million to $18 million per quarter despite competition from bispecific therapies, which have captured about one-third of the market [9] Growth Opportunities - Future growth expected from new indications and regulatory approvals, particularly in indolent lymphomas [9][10] - Impressive Phase II data in indolent lymphoma, with a 77% complete response rate in high-risk follicular lymphoma patients [11][12] - Marginal zone lymphoma study showing a 70% complete response rate, significantly higher than existing therapies [13] Regulatory Pathways - Plans to approach the FDA for regulatory approval based on ongoing studies, with potential guideline inclusion by 2027 [15][14] Clinical Trials - LOTUS 5 Study: Phase III study in second-line DLBCL, completed enrollment, with top-line results expected by the end of the year [19][20] - LOTUS 7 Study: Combination study with glofitimab, showing a 72% complete response rate in early data [29][30] - Safety profile consistent with known profiles of individual drugs, with manageable adverse events [32][34] Market Potential - ZENLANTA plus rituximab could expand market opportunity to $200 million to $300 million, with each share point in second-line therapy worth approximately $15 million [25][26] - Anticipated competitive positioning against CAR T and bispecific therapies due to better safety and accessibility [22][44] Early-Stage Development - ADC Therapeutics is developing a novel Exotecan-based platform targeting claudin 6, PSMA, NaPi2b, and ACT2, all in IND enabling stage [48][50] - Plans to move one product forward to IND while seeking external funding for others [50][51] Future Updates - More updates expected throughout the year regarding IND filings and partnerships for the ADC platform [53]